0000358654
Donate
Active substances for the treatment of:

Malignant bladder cancer

Name of active substance (medicine) The European Society for Medical Oncology (ESMO). Published scientific research demonstrates that the observance of such scientific community guidelines has a positive impact on patient survival rates. Is it included in
the European standard  of treatment (according to ESMO)?
Access status (National Health Fund reimbursement) Additional information
Vinflunine The drug in this indication is not refunded No reimbursement Vinflunine is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. EPAR/SmPC
Atezolizumab The drug in this indication is not refunded No reimbursement Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): • after prior platinum-containing chemotherapy, or • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%. EPAR/SmPC
Nivolumab The drug in this indication is not refunded No reimbursement Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. EPAR/SmPC
Pembrolizumab The drug in this indication is not refunded No reimbursement Pembrolizumab as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. Pembrolizumab as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS)≥ 10 EPAR/SmPC